Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Nicotinamide→

Nicotinamide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
98-92-0
Molecular formula
C6H6N2O
Molecular weight
122.1246 g/mol
Drug class
Vitamin B3 (niacinamide)water-soluble vitamin and NAD/NADP precursor
Mechanism of action
Serves as a precursor for nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP), coenzymes required for redox metabolism, energy production, DNA repair and cellular signalling.
Indications / reported uses
  • Prevention and treatment of niacin deficiency and pellagra
  • Use in other dermatological or metabolic conditions is formulation- and evidence-specific and should not be inferred from the vitamin’s biochemical role alone

Sources: NIH Office of Dietary Supplements — Niacin fact sheet · NHS — Vitamins and minerals: vitamin B3 · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Nicotinamide Environmental Risk Assessment (ERA) (the Nicotinamide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.